Ozempic Launched In India For Type-2 Diabetes
Novo Nordisk has launched Ozempic (Semaglutide) in India, offering weekly doses of 0.25 mg, 0.5 mg, and 1 mg. Approved for type-2 diabetes, it regulates blood sugar by mimicking GLP-1, slows digestion, and reduces appetite. The launch provides accessible, globally recognized treatment amid India’s rising diabetes and obesity rates.